Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint deterioration. Clinical outcomes in patients with active RA can be improved with the use of antirheumatic drugs such as methotrexate (MTX). Many patients rely on MTX to limit the devastating joint damage and functional disability typical of RA. Although the drug is a folate antagonist, its exact mechanism in patients with rheumatoid arthritis is largely unknown.
Previous research has shown that MTX also affects a type of w